Targovax ASA logo

TRVXo - Targovax ASA News Story

NOK6.38 -0.0  -0.6%

Last Trade - 10/08/20

Sector
Healthcare
Size
Micro Cap
Market Cap £41.3m
Enterprise Value £35.7m
Revenue £217k
Position in Universe 1012th / 1782

BRIEF-Targovax's ONCOS-102 Mesothelioma 12-Month Data Demonstrate Broad Immune Activation Linked To Clinical Benefit

Mon 22nd June, 2020 6:04am
June 22 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX'S ONCOS-102 MESOTHELIOMA 12-MONTH DATA POWERFULLY
DEMONSTRATE BROAD IMMUNE ACTIVATION LINKED TO CLINICAL BENEFIT
    * MECHANISTIC EVIDENCE OF PROFOUND IMMUNE ACTIVATION IN
ONCOS-102-TREATED PATIENTS ASSOCIATED WITH BETTER CLINICAL
OUTCOMES
    * IMMUNE ACTIVATION DATA PROVIDES CLEAR SCIENTIFIC RATIONALE
FOR
ANTI-PD1/L1 CHECKPOINT INHIBITOR COMBINATION IN UPCOMING TRIAL
IN FIRST LINE MESOTHELIOMA OSLO, NORWAY, 22 JUNE 2020
    * 12-MONTH SURVIVAL RATE WAS 64% IN FIRST LINE ONCOS-102
TREATED
PATIENTS, COMPARED TO 50% IN FIRST LINE CONTROL GROUP TREATED
WITH SOC CHEMOTHERAPY ONLY (MEDIAN OVERALL SURVIVAL IS TOO EARLY
TO REPORT)

Source text for Eikon:  ID:nWkr4Rm97l 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.